No Data
No Data
Guangdong Zhongsheng Pharmaceutical: 2024 Interim Performance Forecast
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Takes the compound thrombus series products as a whole for targeted marketing layout.
On July 3rd, Gelonhui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced in its investor relations activity that based on the development strategy of core products after the national procurement of Chinese patent medicines, the company has made the following three marketing deployments: firstly, based on the original intention of encouraging medical institutions to choose high-quality, clinically recognized and cost-effective drugs selected in the procurement, the company promotes the channel sinking of its core product, compound thrombolytic agent extrinsic, to cover more county-level, grassroots and retail terminals, and strive for more market share. Secondly, the company regards the compound thrombolytic agent series as a whole for targeted marketing layout, through different specifications in various terminals.
Zhongsheng Pharmaceutical's Unit Gets Nod to Market Gastric Protective Drug
China's National Medical Products Administration granted a drug registration certificate to a gastric mucosal protective drug of Guangdong Zhongsheng Pharmaceutical's (SHE:002317) unit, Huanan Pharmac
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Wholly-owned subsidiary obtains registration certificate for Ribavirin Tablets.
On June 28th, Gelonhui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its wholly-owned subsidiary, Guangdong South Pharmaceutical Group Co., Ltd., recently received the approval and issuance of the Drug Registration Certificate for Rebamipide Tablets from the National Medical Products Administration. Rebamipide tablet is a gastric mucosal protector, which has the function of protecting gastric mucosa and promoting ulcer healing. Rebamipide tablet is a Class B drug in the medical insurance catalog, clinically used to improve acute exacerbation of gastric mucosal lesions (erosion, bleeding, congestion, edema) in acute and chronic gastritis, and for the treatment of gastric ulcers. According to the Minet database, rebamipide tablets from 2021 to...
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) Not Flying Under The Radar
With a price-to-earnings (or "P/E") ratio of 57.8x Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) may be sending very bearish signals at the moment, given that almost half of all companie
Guangdong Zhongsheng Pharmaceutical (002317.SZ) plans to launch an employee shareholding plan in 2024.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) has released a draft of the 2024 employee stock ownership plan, and plans to raise a total of funds...
No Data